News & Updates

Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
09 Aug 2023
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023 byAudrey Abella

In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).

Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023